Context The expression and release of tissue factor is a major trigger for the activation of
coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex
with tissue factor and blood protease factors leading to inhibition of thrombin generation and
fibrin formation. Objectives To determine if administration of tifacogin (recombinant TFPI)
provides mortality benefit in patients with severe sepsis and elevated international
normalized ratio (INR) and to assess tifacogin safety in severe sepsis, including patients with …